(Beta Cell) Stressing You Out?
You thought that beta cells were passive participants in their own immune-mediated death, leading to type 1 diabetes (T1D)? Wrong.
It’s Official: Teplizumab is Under Review by the FDA
The FDA regulatory review is now under way for teplizumab, to prevent or delay T1D in at-risk individuals. The target…
Bringing Type 1 Diabetes Screening to the Public
Breakthrough T1D is launching T1Detect, a community-based education and awareness program to expand screening to the general population.
Microbiome Reset: Clinical Trial in Newly Diagnosed Youth
While genetics play a major role in the development of type 1 diabetes (T1D), mounting evidence supports the strong influence…
Breakthrough T1D Researchers Develop a Combined Risk Score to Predict Which Children Develop T1D
Type 1 diabetes (T1D) can be hard to predict in high risk children. Testing for the presence of T1D autoantibodies—antibodies…
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for…
Dr. Jane Buckner Discusses Hydroxychloroquine T1D Prevention Study
Details about the TrialNet study, including why Hydroxychloroquine, and the status of subject participation.
Public and Private Organizations, All with the Same Goal: End T1D
In this time of great uncertainty, there is some exciting news out of Europe. Innodia, a partnership between public and…
A Promising (Preclinical) Vaccine for Type 1 Diabetes
Wouldn’t it be nice if you could take a vaccine in infancy, and type 1 diabetes would not develop? Preclinical…
Dr. Carla Greenbaum Talks about T1D TrialNet During the COVID-19 Pandemic
Carla Greenbaum, M.D., chair of TrialNet—an international Breakthrough T1D-supported network that is dedicated to finding cures for type 1 diabetes…
